Details

Autor(en) / Beteiligte

• Papadimitriou, Lampros, MD, PhD
• Smith-Jones, Peter M., PhD
• Sarwar, Chaudhry M.S., MD
• Marti, Catherine N., MD
• Yaddanapudi, Kavitha, MD
• Skopicki, Hal A., MD, PhD
• Gheorghiade, Mihai, MD
• Parsey, Ramin, MD, PhD
• Butler, Javed, MD, MPH, MBA

Titel

Utility of Positron Emission Tomography For Drug Development for Heart Failure

Ist Teil von

• The American heart journal, 2016-05, Vol.175, p.142-152

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Abstract Only about one out in 5000 investigational agents in a preclinical stage acquires Food and Drug Administration (FDA) approval. Among many reasons for this includes an inefficient transition from preclinical to clinical phases, which exponentially increase the cost and the delays the process of drug development. Positron emission tomography (PET) is a nuclear imaging technique that has been used for the diagnosis, risk stratification, and guidance of therapy. However lately with the advance of radiochemistry and of molecular imaging technology, it became evident that PET could help novel drug development process. By using a PET radioligand to report on receptor occupancy during novel agent therapy, it may help assess the effectiveness, efficacy, and safety of such a new medication in an early preclinical stage and help design succesful clinical trials even at a later phase. In this paper,we explore the potential implications of PET in the development of new heart failure therapies, and review PET’s application in the respective pathophysiologic pathways such as myocardial perfusion, metabolism, innervation, inflammation, apoptosis and cardiac remodeling.